Canine Mitral Valve Disease: Diagnosis and Management

Myxomatous mitral valve disease (MMVD) is the most common acquired heart disease in dogs, particularly affecting small to medium breeds. This article provides veterinarians with an evidence-based framework for diagnosing, staging, and managing MMVD using the American College of Veterinary Internal Medicine (ACVIM) consensus guidelines. The focus is on practical clinical decisions, from auscultation findings through echocardiographic staging to medical therapy, with clear escalation criteria for specialist referral.

At a Glance: MMVD Staging and Management Overview

Pathophysiology and Breed Predisposition

MMVD involves progressive myxomatous degeneration of the mitral valve leaflets, leading to valve thickening, prolapse, and regurgitation. The mitral valve apparatus includes the leaflets, chordae tendineae, papillary muscles, and annulus. Degeneration causes chordal elongation or rupture, leaflet billowing, and incomplete coaptation during systole. The resulting regurgitant jet volume increases left atrial pressure and volume overload, triggering compensatory eccentric hypertrophy and neurohormonal activation.

Breed predisposition is well documented. Cavalier King Charles Spaniels show the highest prevalence, often developing murmurs by 5-6 years of age. Dachshunds, Miniature Poodles, Chihuahuas, and Cocker Spaniels are also overrepresented. The Merck Veterinary Manual notes that small breed dogs under 20 kg are most commonly affected, though large breeds can develop MMVD as well. The ACVIM consensus guidelines emphasize that breed-specific screening protocols should be considered for high-risk populations.

Diagnostic Workup

Auscultation and Physical Examination

The initial detection of MMVD typically occurs during routine auscultation. A left apical systolic murmur is the hallmark finding, with intensity graded I through VI. Murmur grade correlates imperfectly with disease severity. A grade III or louder murmur that radiates widely warrants further investigation. The Merck Veterinary Manual advises that a soft grade I-II murmur in a young dog may be physiologic, but any murmur in a middle-aged or older small breed dog should raise suspicion for MMVD.

Physical examination should include assessment of femoral pulse quality, mucous membrane color, capillary refill time, jugular vein distension, and lung auscultation for crackles. The presence of a gallop rhythm or arrhythmia suggests advanced disease. Body condition scoring is important because obesity exacerbates respiratory effort in heart failure.

Thoracic Radiography

Thoracic radiographs are essential for evaluating cardiomegaly and pulmonary changes. The vertebral heart score (VHS) is measured on a right lateral view by summing the long axis and short axis of the cardiac silhouette and comparing to the length of thoracic vertebrae. A VHS greater than 10.5 is considered cardiomegaly in most breeds. Left atrial enlargement is best assessed on the dorsoventral or ventrodorsal view, where the left auricle may create a bulge at the 2-3 o'clock position.

Radiographic signs of congestive heart failure include pulmonary venous distension, interstitial or alveolar pulmonary edema, and pleural effusion. The ACVIM consensus guidelines recommend thoracic radiography for all dogs with a heart murmur to differentiate preclinical from clinical disease. However, early-stage MMVD is challenging to identify on radiographs alone, as noted in research on deep learning-based detection for MMVD staging.

Echocardiography

Echocardiography is the gold standard for MMVD diagnosis and staging. The ACVIM consensus guidelines provide specific criteria for each stage based on echocardiographic measurements. Key parameters include:

• Left atrium to aorta ratio (LA:Ao) measured from the right parasternal short-axis view. An LA:Ao greater than 1.6 indicates left atrial enlargement.
• Left ventricular internal diameter in diastole normalized to body weight (LVIDDN). Values greater than 1.7 indicate left ventricular enlargement.
• Mitral valve morphology, including leaflet thickness, prolapse, and chordal integrity.
• Regurgitant jet area and vena contracta width on color Doppler.

Quantitative regurgitant indices such as regurgitant volume and regurgitant fraction provide additional information about functional severity. Research shows that regurgitant volume normalized to body weight and regurgitant fraction increase significantly with advancing ACVIM stage. However, severe mitral regurgitation (regurgitant fraction ≥50%) can occur in some dogs classified as stage B1, indicating that conventional staging may underestimate functional severity in individual patients.

Electrocardiography

Electrocardiography is a low-cost, widely accessible technology that may have a role in MMVD screening. The R-peak time (RPT) measured on lead II has been investigated as a potential screening tool. Research shows that RPT differs between ACVIM stages, with positive correlation to disease stage and cardiac dimensions. An optimal RPT cutoff of 30 milliseconds distinguished dogs that would benefit from treatment (stages B2, C, D) from those that would not (stages A, B1) with an area under the curve of 0.935. While RPT is not suggested as a replacement for echocardiography, it may be useful for screening where echocardiography is unavailable.

Cardiac Biomarkers

Cardiac troponin I (cTnI) is a well-established biomarker of myocardial injury. N-terminal pro-B-type natriuretic peptide (NT-proBNP) reflects myocardial stretch and is useful for differentiating cardiac from respiratory causes of dyspnea. The ACVIM consensus guidelines recommend NT-proBNP measurement when echocardiography is not available or when clinical signs are equivocal.

Emerging biomarkers include trimethylamine N-oxide (TMAO) and galectin-3. Preliminary research found that TMAO levels were significantly higher in both asymptomatic and symptomatic MMVD dogs compared to healthy controls, suggesting a potential role in disease progression monitoring. Galectin-3 showed no significant differences between groups in the same study.

MicroRNA expression profiling is another investigational approach. Research using 15 selected miRNA markers achieved 83% accuracy in distinguishing healthy controls from MMVD cases, with 85% sensitivity and 82% specificity. For discriminating preclinical (stage B1/B2) from clinical (stage C/D) disease, accuracy was 73%. These findings suggest miRNA panels may become a useful adjunctive diagnostic tool.

ACVIM Staging System

The ACVIM consensus guidelines define four clinical stages for MMVD:

Stage A: Dogs at high risk for developing MMVD but without structural heart disease. This includes Cavalier King Charles Spaniels and other predisposed breeds. No therapy is indicated, but client education about heart murmur detection and annual screening is recommended.

Stage B: Dogs with structural heart disease but no current or past signs of congestive heart failure. This stage is subdivided into B1 and B2.

• Stage B1: Asymptomatic dogs with a heart murmur but no radiographic or echocardiographic evidence of cardiomegaly. No medical therapy is indicated. Monitoring every 6-12 months is recommended.

• Stage B2: Asymptomatic dogs with a heart murmur and evidence of cardiomegaly. The EPIC trial demonstrated that pimobendan therapy delays the onset of congestive heart failure in these dogs. Initiation of pimobendan is recommended when echocardiographic criteria are met: LA:Ao ≥1.6, LVIDDN ≥1.7, and VHS >10.5.

Stage C: Dogs with current or past clinical signs of congestive heart failure. Standard therapy includes pimobendan, furosemide, an ACE inhibitor, and spironolactone. Monitoring every 1-3 months is recommended.

Stage D: Dogs with refractory congestive heart failure despite standard therapy. Advanced treatment options include higher diuretic doses, additional vasodilators, and consideration of surgical mitral valve repair.

Medical Management

Pimobendan

Pimobendan is a calcium sensitizer and phosphodiesterase III inhibitor that increases myocardial contractility and causes vasodilation. The EPIC trial established its efficacy in delaying the onset of congestive heart failure in dogs with preclinical MMVD and cardiomegaly. The study showed that pimobendan significantly prolonged the time to heart failure onset, cardiac-related death, or euthanasia.

For stage B2 dogs, pimobendan monotherapy is the standard of care. Research on echocardiographic changes in stage B2 dogs treated with pimobendan monotherapy has documented improvements in cardiac dimensions and function. The EPIC trial also evaluated quality of life, radiographic, echocardiographic, and laboratory variables, finding that pimobendan-treated dogs maintained better clinical status over time.

For stage C and D dogs, pimobendan is combined with other heart failure medications. The combination of pimobendan, furosemide, and enalapril has been studied for its impact on heart rate variability in symptomatic MMVD dogs.

A note of caution: long-term pimobendan therapy has been associated with increased mitral valve regurgitation and myocardial hypertrophy in some dogs. While this finding comes from a small case series, it underscores the importance of regular monitoring and echocardiographic reassessment.

ACE Inhibitors

Angiotensin-converting enzyme (ACE) inhibitors such as enalapril and benazepril reduce afterload and decrease neurohormonal activation. The ACVIM consensus guidelines recommend ACE inhibitors for stage C and D dogs as part of combination therapy. Their role in stage B2 is less clear, the EPIC trial used pimobendan alone, and ACE inhibitors are not routinely recommended for preclinical disease without cardiomegaly.

Diuretics

Furosemide is the primary diuretic for managing pulmonary edema in congestive heart failure. The ACVIM consensus guidelines recommend starting at a dose that achieves clinical resolution of edema, then tapering to the lowest effective maintenance dose. Spironolactone, an aldosterone antagonist, is added for its neurohormonal blocking effects and mild diuretic action. Torsemide may be used in refractory cases.

Emerging Therapies

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are being investigated for canine MMVD. Research has explored the prospects of these drugs for dogs, focusing on finding the right drug and the right dose. While not yet standard of care, this class may offer future therapeutic options.

Surgical Mitral Valve Repair

Mitral valve repair with artificial chordae and annuloplasty is an advanced surgical option for dogs with severe MMVD. Research on long-term outcomes shows that this procedure can be successful in appropriately selected candidates. However, it requires specialized surgical expertise, cardiopulmonary bypass, and significant financial investment. Referral to a veterinary cardiology and cardiac surgery center is necessary for consideration.

Monitoring and Follow-Up

Frequency of Reassessment

The ACVIM consensus guidelines recommend the following monitoring intervals:

• Stage B1: Every 6-12 months with auscultation and thoracic radiography. Echocardiography every 12-24 months or if clinical signs change.
• Stage B2: Every 6 months with echocardiography, thoracic radiography, and physical examination.
• Stage C: Every 1-3 months with physical examination, thoracic radiography, and echocardiography as needed.
• Stage D: As needed based on clinical status, often weekly to monthly.

Parameters to Monitor

• Body weight and body condition score
• Heart rate and rhythm
• Respiratory rate and effort
• Mucous membrane color and capillary refill time
• Jugular vein distension
• Lung auscultation for crackles
• Femoral pulse quality
• Vertebral heart score on radiographs
• LA:Ao and LVIDDN on echocardiography
• Renal function and electrolytes if on diuretics or ACE inhibitors

Home Monitoring

Client education on resting respiratory rate monitoring is essential. Owners should count breaths while the dog is sleeping or resting quietly. A resting respiratory rate consistently above 30 breaths per minute warrants veterinary evaluation. The Merck Veterinary Manual provides guidance for owners on recognizing signs of heart failure progression.

Common Failure Patterns

Delayed Diagnosis

The most common failure is missing early-stage MMVD. A soft murmur in a predisposed breed may be dismissed as insignificant. Regular auscultation at every wellness visit is critical. Any murmur in a middle-aged small breed dog should prompt thoracic radiography and echocardiography.

Inappropriate Staging

Misclassification between stage B1 and B2 leads to either unnecessary treatment or missed opportunity for early intervention. Accurate echocardiographic measurements are essential. The ACVIM consensus guidelines provide clear cutoff values, but operator variability can affect results. Referral to a board-certified cardiologist is recommended when staging is uncertain.

Inadequate Monitoring

Once therapy is initiated, regular reassessment is necessary to detect progression. Dogs in stage B2 on pimobendan should be rechecked every 6 months. Owners may become complacent when the dog appears normal. Emphasize that MMVD is progressive and that medication adjustments may be needed.

Diuretic Mismanagement

Overdiuresis can cause prerenal azotemia, weakness, and electrolyte disturbances. Underdiuresis leads to persistent pulmonary edema. The ACVIM consensus guidelines recommend titrating furosemide to the lowest effective dose. Renal function and electrolytes should be monitored periodically.

Failure to Recognize Refractory Disease

Stage D dogs require advanced management. If a dog continues to show signs of congestive heart failure despite standard therapy, referral to a cardiologist is indicated. Options include torsemide, pimobendan dose adjustment, and surgical evaluation.

Limitations and Professional Escalation Criteria

When to Refer to a Cardiologist

• Uncertainty in echocardiographic staging
• Suspected chordae tendineae rupture
• Refractory congestive heart failure
• Consideration of surgical mitral valve repair
• Complex arrhythmias
• Syncope or collapse
• Poor response to standard therapy

Limitations of Current Evidence

The EPIC trial established pimobendan efficacy for stage B2 dogs with specific echocardiographic criteria. However, not all dogs with cardiomegaly meet the exact EPIC inclusion criteria. Clinical judgment is required for borderline cases. The ACVIM consensus guidelines acknowledge that some dogs may benefit from pimobendan even if they do not meet strict criteria.

Quantitative regurgitant indices such as regurgitant volume and regurgitant fraction may identify dogs with severe mitral regurgitation despite being classified as stage B1. The clinical significance of this finding is not yet fully established, but it suggests that functional severity may be underestimated in some patients.

Emerging biomarkers and imaging techniques are promising but not yet standard of care. MicroRNA panels, TMAO measurement, and deep learning-based image analysis may become useful adjuncts but should not replace echocardiography at this time.

Practical Decision Framework for MMVD Management: A Structured Approach to Staging, Therapy Initiation, and Monitoring

Managing canine myxomatous mitral valve disease requires consistent application of evidence-based criteria across multiple clinical encounters. The ACVIM consensus guidelines provide the staging framework, but translating these guidelines into daily practice demands a systematic decision process that accounts for measurement variability, patient-specific factors, and resource limitations. This section presents a practical decision framework designed for general practitioners, including a structured record system, troubleshooting methods for common diagnostic challenges, and clear escalation criteria.

Structured Clinical Decision Algorithm

The following algorithm integrates auscultation findings, radiographic measurements, echocardiographic parameters, and clinical signs into a stepwise decision pathway. This approach minimizes the risk of misclassification between stages B1 and B2, which is the most common source of therapeutic error.

Step 1: Initial Detection and Risk Stratification

Any dog presenting for wellness examination or unrelated illness should receive systematic cardiac auscultation. For small breed dogs over five years of age, particularly Cavalier King Charles Spaniels, Dachshunds, Miniature Poodles, and Chihuahuas, auscultation should be performed in a quiet room with the dog standing and restrained minimally. The Merck Veterinary Manual recommends listening over the left apex (fifth intercostal space) and left base (third to fourth intercostal space) for systolic murmurs.

When a systolic murmur is detected, document the following in the medical record:

• Murmur grade (I through VI)
• Point of maximal intensity
• Radiation pattern
• Presence of a gallop rhythm or arrhythmia

A grade III or louder murmur that radiates to the right hemithorax warrants immediate thoracic radiography and echocardiography. A soft grade I to II murmur in a young dog may be physiologic, but in a middle-aged or older small breed dog, it should be considered pathologic until proven otherwise.

Step 2: Radiographic Assessment

Obtain three-view thoracic radiographs: right lateral, left lateral, and dorsoventral or ventrodorsal projections. The right lateral view is preferred for vertebral heart score measurement because it minimizes magnification of the cardiac silhouette.

Calculate the vertebral heart score by measuring the long axis from the ventral border of the left mainstem bronchus to the cardiac apex, and the short axis at the widest point perpendicular to the long axis. Sum these measurements and compare to the length of the thoracic vertebrae starting at T4. A VHS greater than 10.5 indicates cardiomegaly in most breeds, though breed-specific reference ranges exist. Cavalier King Charles Spaniels may have a normal VHS up to 10.7, while deep-chested breeds may have lower normal values.

Assess for left atrial enlargement on the dorsoventral view by evaluating the left auricular bulge at the 2 to 3 o'clock position. Pulmonary venous distension, where the pulmonary veins are larger than the corresponding arteries, suggests elevated left atrial pressure. Interstitial or alveolar pulmonary edema indicates congestive heart failure.

Document the following in the medical record:

• Vertebral heart score
• Presence or absence of left atrial enlargement
• Pulmonary venous distension
• Pulmonary edema pattern
• Pleural effusion

Step 3: Echocardiographic Staging

Echocardiography is the gold standard for MMVD staging. The ACVIM consensus guidelines provide specific criteria for each stage. Perform a standard echocardiographic examination including two-dimensional, M-mode, and Doppler studies.

Key measurements for staging:

• Left atrium to aorta ratio measured from the right parasternal short-axis view at the level of the aortic valve. An LA:Ao greater than 1.6 indicates left atrial enlargement.
• Left ventricular internal diameter in diastole normalized to body weight. Values greater than 1.7 indicate left ventricular enlargement.
• Mitral valve morphology: leaflet thickness, prolapse, and chordal integrity.
• Regurgitant jet area and vena contracta width on color Doppler.

Quantitative regurgitant indices provide additional information about functional severity. Research shows that regurgitant volume normalized to body weight and regurgitant fraction increase significantly with advancing ACVIM stage. However, severe mitral regurgitation (regurgitant fraction ≥50%) can occur in some dogs classified as stage B1, indicating that conventional staging may underestimate functional severity in individual patients.

Document the following in the medical record:

• LA:Ao ratio
• LVIDDN
• Mitral valve morphology
• Regurgitant jet description
• Quantitative regurgitant indices if measured
• Ejection fraction or fractional shortening

Step 4: Clinical Classification

Integrate the findings from auscultation, radiography, and echocardiography to assign the ACVIM stage:

• Stage A: Breed predisposition, no heart murmur, normal radiographs and echocardiogram.
• Stage B1: Heart murmur present, VHS ≤10.5, LA:Ao <1.6, LVIDDN <1.7, no clinical signs.
• Stage B2: Heart murmur present, VHS >10.5, LA:Ao ≥1.6, LVIDDN ≥1.7, no clinical signs.
• Stage C: Current or past clinical signs of congestive heart failure (pulmonary edema, pleural effusion, exercise intolerance, cough, dyspnea).
• Stage D: Refractory congestive heart failure despite standard therapy.

Step 5: Therapy Initiation Decision

For stage B2 dogs, initiate pimobendan therapy based on the EPIC trial evidence. The EPIC trial demonstrated that pimobendan significantly prolongs the time to onset of congestive heart failure, cardiac-related death, or euthanasia in dogs with preclinical MMVD and cardiomegaly. The recommended dose is 0.25 to 0.3 mg/kg orally every 12 hours.

For stage C dogs, initiate combination therapy including:

• Pimobendan 0.25 to 0.3 mg/kg orally every 12 hours
• Furosemide 2 to 4 mg/kg orally every 8 to 12 hours, titrated to effect
• ACE inhibitor (enalapril or benazepril) 0.5 mg/kg orally every 12 to 24 hours
• Spironolactone 1 to 2 mg/kg orally every 12 to 24 hours

For stage D dogs, consider advanced therapy options including higher diuretic doses, torsemide, additional vasodilators, and referral for surgical mitral valve repair.

Record System for Longitudinal Monitoring

A structured record system is essential for tracking disease progression and treatment response. The following template can be integrated into the medical record or used as a separate monitoring sheet.

MMVD Monitoring Record Template

Patient Information

• Name, breed, age, weight
• Date of initial diagnosis
• ACVIM stage at diagnosis

Visit Date: _______________

Physical Examination

• Body weight: ________ kg
• Body condition score: ___/9
• Heart rate: ___ bpm
• Respiratory rate: ___ breaths per minute
• Mucous membrane color: pink/pale/cyanotic
• Capillary refill time: ___ seconds
• Jugular vein distension: yes/no
• Lung auscultation: clear/crackles/wheezes
• Femoral pulse quality: strong/weak/absent
• Murmur grade: I/II/III/IV/V/VI
• Gallop rhythm: yes/no
• Arrhythmia: yes/no

Thoracic Radiography

• Vertebral heart score: ___
• Left atrial enlargement: yes/no
• Pulmonary venous distension: yes/no
• Pulmonary edema: yes/no
• Pleural effusion: yes/no

Echocardiography

• LA:Ao: ___
• LVIDDN: ___
• Mitral valve morphology: normal/thickened/prolapsed
• Regurgitant jet: mild/moderate/severe
• Ejection fraction: ___%
• Fractional shortening: ___%

Laboratory Values

• BUN: ___ mg/dL
• Creatinine: ___ mg/dL
• Sodium: ___ mEq/L
• Potassium: ___ mEq/L
• Chloride: ___ mEq/L

Current Medications

• Pimobendan: dose, frequency
• Furosemide: dose, frequency
• ACE inhibitor: dose, frequency
• Spironolactone: dose, frequency
• Other: dose, frequency

Owner Assessment

• Resting respiratory rate: ___ breaths per minute
• Exercise tolerance: normal/decreased/poor
• Cough: none/mild/moderate/severe
• Appetite: normal/decreased/poor
• Activity level: normal/decreased/poor

ACVIM Stage: A/B1/B2/C/D

Plan

• Medication adjustments: _______________
• Next recheck: _______________
• Referral to cardiologist: yes/no

Troubleshooting Common Diagnostic Challenges

Challenge 1: Borderline Echocardiographic Measurements

When LA:Ao or LVIDDN values fall near the cutoff thresholds (LA:Ao 1.55 to 1.65, LVIDDN 1.65 to 1.75), staging uncertainty arises. The ACVIM consensus guidelines acknowledge that some dogs may benefit from pimobendan even if they do not meet strict EPIC criteria.

Approach:

• Repeat measurements on a different day to assess variability.
• Consider quantitative regurgitant indices. Research shows that regurgitant fraction ≥50% can occur in some stage B1 dogs, suggesting functional severity may be underestimated.
• Evaluate the trend over time. A dog with measurements approaching but not exceeding thresholds that shows progressive increase may benefit from early intervention.
• Discuss with the owner the uncertainty and the evidence for pimobendan in stage B2 dogs. Document the decision and rationale.

Challenge 2: Murmur Grade Does Not Match Echocardiographic Severity

A soft murmur (grade I to II) with significant cardiomegaly on echocardiography, or a loud murmur (grade V to VI) with minimal remodeling, can occur. Murmur grade correlates imperfectly with disease severity.

Approach:

• Rely on echocardiographic measurements for staging, not murmur intensity.
• Consider that a loud murmur with minimal remodeling may indicate a small regurgitant orifice with high velocity, which can still be hemodynamically significant.
• A soft murmur with significant remodeling may indicate reduced cardiac output or a large regurgitant orifice with low velocity.
• Quantitative regurgitant indices may clarify functional severity in these cases.

Challenge 3: Radiographic Cardiomegaly Without Echocardiographic Cardiomegaly

Occasionally, the VHS exceeds 10.5 but LA:Ao and LVIDDN are below thresholds. This can occur with pericardial fat, breed variation, or concurrent conditions such as obesity or respiratory disease.

Approach:

• Verify radiographic technique and measurement accuracy.
• Consider breed-specific VHS reference ranges.
• Evaluate for other causes of radiographic cardiomegaly, such as pericardial effusion or other cardiac diseases.
• If echocardiographic measurements are clearly below thresholds, classify as stage B1 and monitor.

Challenge 4: Clinical Signs Without Cardiomegaly

A dog with cough, exercise intolerance, or dyspnea but normal VHS, LA:Ao, and LVIDDN may have respiratory disease instead of heart failure. Differentiating cardiac from respiratory causes of dyspnea is critical.

Approach:

• Measure NT-proBNP. The ACVIM consensus guidelines recommend NT-proBNP measurement when echocardiography is not available or when clinical signs are equivocal.
• Perform thoracic radiography to evaluate for pulmonary disease.
• Consider bronchomalacia, which can cause cough in small breed dogs. Research on lower airway collapse has revisited the definition and clinicopathologic features of canine bronchomalacia.
• If NT-proBNP is elevated and respiratory disease is excluded, consider early-stage MMVD with atypical presentation.

Challenge 5: Poor Response to Standard Therapy

A stage C dog that continues to show signs of congestive heart failure despite pimobendan, furosemide, ACE inhibitor, and spironolactone requires advanced management.

Approach:

• Verify medication compliance and dosing.
• Increase furosemide dose or switch to torsemide.
• Consider adding a second diuretic such as hydrochlorothiazide.
• Evaluate for concurrent conditions such as arrhythmias, pulmonary hypertension, or renal disease.
• Refer to a cardiologist for advanced imaging and treatment options.

Common Failure Patterns in MMVD Management

Failure Pattern 1: Delayed Diagnosis

The most common failure is missing early-stage MMVD. A soft murmur in a predisposed breed may be dismissed as insignificant. Regular auscultation at every wellness visit is critical. Any murmur in a middle-aged small breed dog should prompt thoracic radiography and echocardiography.

Prevention:

• Implement a screening protocol for all small breed dogs over five years of age.
• Educate owners about the importance of annual cardiac auscultation.
• Use a heart murmur grading system consistently.

Failure Pattern 2: Inappropriate Staging

Misclassification between stage B1 and B2 leads to either unnecessary treatment or missed opportunity for early intervention. Accurate echocardiographic measurements are essential. The ACVIM consensus guidelines provide clear cutoff values, but operator variability can affect results.

Prevention:

• Use standardized echocardiographic protocols.
• Repeat measurements if values are borderline.
• Consider quantitative regurgitant indices for additional information.
• Refer to a board-certified cardiologist when staging is uncertain.

Failure Pattern 3: Inadequate Monitoring

Once therapy is initiated, regular reassessment is necessary to detect progression. Dogs in stage B2 on pimobendan should be rechecked every six months. Owners may become complacent when the dog appears normal.

Prevention:

• Schedule recheck appointments at the time of therapy initiation.
• Educate owners about the progressive nature of MMVD.
• Provide a home monitoring log for resting respiratory rate.

Failure Pattern 4: Diuretic Mismanagement

Overdiuresis can cause prerenal azotemia, weakness, and electrolyte disturbances. Underdiuresis leads to persistent pulmonary edema. The ACVIM consensus guidelines recommend titrating furosemide to the lowest effective dose.

Prevention:

• Monitor renal function and electrolytes periodically.
• Adjust furosemide dose based on clinical signs and body weight.
• Use the lowest effective maintenance dose.
• Educate owners about signs of overdiuresis (weakness, lethargy, decreased appetite) and underdiuresis (cough, increased respiratory effort).

Failure Pattern 5: Failure to Recognize Refractory Disease

Stage D dogs require advanced management. If a dog continues to show signs of congestive heart failure despite standard therapy, referral to a cardiologist is indicated.

Prevention:

• Recognize the criteria for stage D: refractory congestive heart failure despite standard therapy.
• Consider advanced treatment options including torsemide, pimobendan dose adjustment, and surgical evaluation.
• Refer to a cardiologist early in the course of refractory disease.

Welfare and Safety Context

MMVD management must balance therapeutic benefit with quality of life. The ACVIM consensus guidelines emphasize that treatment decisions should consider the individual patient's clinical status, owner resources, and welfare implications.

Quality of Life Assessment

Regular quality of life assessment is essential for dogs with MMVD. The EPIC trial evaluated quality of life using a standardized questionnaire and found that pimobendan-treated dogs maintained better clinical status over time. For clinical practice, a simple quality of life assessment can include:

• Appetite and food intake
• Activity level and exercise tolerance
• Cough frequency and severity
• Resting respiratory rate
• Sleep quality
• Owner perception of overall well-being

Document quality of life assessments at each recheck and adjust therapy accordingly.

End-of-Life Considerations

As MMVD progresses to stage D, owners may face difficult decisions about euthanasia. The ACVIM consensus guidelines recommend discussing prognosis and end-of-life care early in the disease course. Factors to consider include:

• Refractory congestive heart failure despite maximal therapy
• Poor quality of life with persistent dyspnea, cough, or exercise intolerance
• Frequent emergency visits for heart failure episodes
• Owner burden and financial constraints

Provide compassionate guidance and support for end-of-life decisions.

Safety Considerations for Medical Therapy

Pimobendan is generally well tolerated, but long-term therapy has been associated with increased mitral valve regurgitation and myocardial hypertrophy in some dogs. While this finding comes from a small case series, it underscores the importance of regular monitoring and echocardiographic reassessment.

Furosemide can cause electrolyte disturbances, prerenal azotemia, and dehydration. Monitor renal function and electrolytes periodically, especially in dogs on high doses or combination diuretic therapy.

ACE inhibitors can cause hypotension, azotemia, and hyperkalemia. Monitor blood pressure and renal function after initiating therapy and after dose adjustments.

Spironolactone can cause hyperkalemia, especially when combined with ACE inhibitors. Monitor potassium levels periodically.

Professional Escalation Criteria

Referral to a board-certified cardiologist is indicated in the following situations:

• Uncertainty in echocardiographic staging, particularly borderline measurements between stage B1 and B2
• Suspected chordae tendineae rupture, which can cause acute severe mitral regurgitation and pulmonary edema
• Refractory congestive heart failure despite standard therapy
• Consideration of surgical mitral valve repair
• Complex arrhythmias, including atrial fibrillation or ventricular tachycardia
• Syncope or collapse
• Poor response to standard therapy
• Need for advanced diagnostic imaging such as transesophageal echocardiography

The ACVIM consensus guidelines recommend that general practitioners develop a relationship with a veterinary cardiologist for consultation and referral. Early referral, before the onset of refractory disease, improves outcomes and allows for more treatment options.

Limitations of Current Evidence

The EPIC trial established pimobendan efficacy for stage B2 dogs with specific echocardiographic criteria. However, not all dogs with cardiomegaly meet the exact EPIC inclusion criteria. Clinical judgment is required for borderline cases. The ACVIM consensus guidelines acknowledge that some dogs may benefit from pimobendan even if they do not meet strict criteria.

Quantitative regurgitant indices such as regurgitant volume and regurgitant fraction may identify dogs with severe mitral regurgitation despite being classified as stage B1. The clinical significance of this finding is not yet fully established, but it suggests that functional severity may be underestimated in some patients.

Emerging biomarkers and imaging techniques are promising but not yet standard of care. MicroRNA panels, TMAO measurement, and deep learning-based image analysis may become useful adjuncts but should not replace echocardiography at this time.

Research on SGLT2 inhibitors for canine MMVD is ongoing, with studies focusing on finding the right drug and the right dose for dogs. While not yet standard of care, this class may offer future therapeutic options.

Surgical mitral valve repair with artificial chordae and annuloplasty is an advanced option for selected cases. Research on long-term outcomes shows that this procedure can be successful, but it requires specialized surgical expertise, cardiopulmonary bypass, and significant financial investment. Referral to a veterinary cardiology and cardiac surgery center is necessary for consideration.

Frequently Asked Questions

What is the difference between stage B1 and B2 MMVD?

Stage B1 indicates a heart murmur without cardiomegaly on radiographs or echocardiography. Stage B2 indicates a heart murmur with evidence of cardiomegaly, specifically LA:Ao ≥1.6, LVIDDN ≥1.7, and VHS >10.5. The distinction is critical because the EPIC trial showed that pimobendan therapy delays heart failure onset only in stage B2 dogs.

When should I start pimobendan in a dog with MMVD?

Pimobendan should be started when a dog meets ACVIM stage B2 criteria: a heart murmur with echocardiographic evidence of cardiomegaly (LA:Ao ≥1.6, LVIDDN ≥1.7) and radiographic cardiomegaly (VHS >10.5). The EPIC trial demonstrated that pimobendan significantly prolongs the time to congestive heart failure in these dogs.

Can MMVD be reversed or cured?

MMVD is a progressive degenerative disease that cannot be reversed or cured. Medical therapy aims to delay the onset of congestive heart failure and improve quality of life. Surgical mitral valve repair is an option for selected cases but requires specialized expertise and is not widely available.

How often should I recheck a dog with stage B2 MMVD?

The ACVIM consensus guidelines recommend rechecking stage B2 dogs every 6 months with physical examination, thoracic radiography, and echocardiography. More frequent monitoring may be needed if clinical signs change or if the dog is approaching stage C.

What is the role of ACE inhibitors in MMVD?

ACE inhibitors are recommended for stage C and D dogs as part of combination therapy for congestive heart failure. Their role in stage B2 is not established, the EPIC trial used pimobendan alone. ACE inhibitors are not routinely recommended for preclinical disease without cardiomegaly.

How do I monitor a dog on diuretic therapy?

Monitor body weight, resting respiratory rate, renal function (BUN, creatinine), and electrolytes (sodium, potassium, chloride). The ACVIM consensus guidelines recommend titrating furosemide to the lowest effective dose. Overdiuresis causes prerenal azotemia and weakness, underdiuresis allows persistent pulmonary edema.

What is the prognosis for a dog with stage C MMVD?

With appropriate medical therapy, many dogs with stage C MMVD have a good quality of life for months to years. The ACVIM consensus guidelines report that median survival time for stage C dogs on standard therapy is approximately 9-12 months, but individual outcomes vary widely. Regular monitoring and medication adjustments are essential.

When should I refer a dog with MMVD to a cardiologist?

Referral is indicated for uncertain staging, suspected chordae tendineae rupture, refractory congestive heart failure, consideration of surgical repair, complex arrhythmias, syncope, or poor response to standard therapy. A board-certified cardiologist can provide advanced diagnostic imaging and treatment options.

Related Veterinary Guides

• Dog
• Canine Hyperadrenocorticism Cushings Diagnostic Management
• Dog Shedding Management
• How To Skin A Dog
• Dog Kidney Disease Diet

References and Further Reading

• www.merckvetmanual.com
• www.aaha.org
• www.acvim.org
• Merck Veterinary Manual. Merck Veterinary Manual.
• Animal Health and Welfare. World Organisation for Animal Health.
• ACVIM consensus guidelines for the diagnosis and treatment of myxomatous mitral valve disease in dogs.. Journal of veterinary internal medicine, 2019.
• Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.. Journal of veterinary internal medicine, 2016.
• Sodium-glucose co-transporter 2 inhibitors: Prospects for canine myxomatous mitral valve disease and finding the "right drug" and the "right dose" for dogs.. The Journal of veterinary medical science, 2025.
• Lower airway collapse: Revisiting the definition and clinicopathologic features of canine bronchomalacia.. Veterinary journal (London, England : 1997), 2021.
• Long-Term Outcomes of Mitral Valve Repair With Artificial Chordae and Annuloplasty for Myxomatous Mitral Valve Disease in Dogs.. Journal of veterinary internal medicine, 2025.
• Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.. Journal of veterinary internal medicine, 2018.
• Using a Spectrum of Care Approach to the Diagnosis and Staging of Canine Myxomatous Mitral Valve Disease. Advances in Small Animal Care, 2025.
• R-peak time in different clinical stages of canine myxomatous mitral valve disease. Acta Veterinaria Brasilica, 2024.
• Quantitative mitral regurgitation and conventional echocardiographic variables in canine myxomatous mitral valve disease. Frontiers in Veterinary Science, 2026.
• Canine radiography and echocardiography sensor fusion for deep learning-based detection and classification of myxomatous mitral valve disease. Journal of Thoracic Disease, 2026.
• Assessing the use of blood microRNA expression patterns for predictive diagnosis of myxomatous mitral valve disease in dogs. Frontiers in Veterinary Science, 2024.
• Clinical Value of Serum Cardiac Troponin I, Trimethylamine N-Oxide (TMAO), and Galectin-3 in Canine Myxomatous Mitral Valve Degeneration: A Preliminary Study. Veterinary Sciences, 2026.
• Emulating the EPIC trial using VetCompass primary-care data: causal effects of pimobendan in UK dogs with grade IV/VI heart murmurs. Plos One, 2025.
• Echocardiographic Changes in Dogs with Stage B2 Myxomatous Mitral Valve Disease Treated with Pimobendan Monotherapy. Veterinary Sciences, 2024.
• Increased mitral valve regurgitation and myocardial hypertrophy in two dogs with long-term pimobendan therapy. Cardiovascular Toxicology, 2005.
• Effect of pimobendan on physical fitness, lactate and echocardiographic parameters in dogs with preclinical mitral valve disease without cardiomegaly. Plos One, 2019.
• Impact of a combination of pimobendan, furosemide, and enalapril on heart rate variability in naturally occurring, symptomatic, myxomatous mitral valve degeneration dogs. BMC Veterinary Research, 2023.

This article is educational and is not a substitute for veterinary diagnosis or treatment. Contact a veterinarian for advice about an individual animal.